Global Finance News
06 Mar 2026, 09:47
Vertex Pharmaceuticals reported new Phase 4 study data showing its non-opioid pain drug JOURNAVX enabled opioid-free recovery in most patients following aesthetic and reconstructive surgeries.
In the study of 99 patients, 90.9% remained opioid-free for up to 14 days after surgery when JOURNAVX was used as part of multimodal pain treatment with medicines such as acetaminophen and ibuprofen. About 90.7% of patients rated the treatment’s effectiveness as excellent, very good, or good.
The company said the results highlight the drug’s potential to support opioid-free pain management after surgery. The findings will be presented at the American Academy of Pain Medicine’s PainConnect 2026 meeting.
Business Wire
In the study of 99 patients, 90.9% remained opioid-free for up to 14 days after surgery when JOURNAVX was used as part of multimodal pain treatment with medicines such as acetaminophen and ibuprofen. About 90.7% of patients rated the treatment’s effectiveness as excellent, very good, or good.
The company said the results highlight the drug’s potential to support opioid-free pain management after surgery. The findings will be presented at the American Academy of Pain Medicine’s PainConnect 2026 meeting.
Business Wire
